News/Events

LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Has a Favorable Risk-Benefit Profile vs. Prednisone and Placebo in a First in Human Study

LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates

Immune-Targeted Glucocorticoid ADC for the Treatment of Autoimmune and Inflammatory Diseases